Innate challenges Pfizer in Nectin-4
While Cogent joins the FGFR party.
Zai Lab looks towards an accelerated pathway
The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.
Mersana shows that B7-H4 expression matters
The latest B7-H4 ADC shows activity only in biomarker-positive patients.
Zai Lab takes a second punt on MediLink
And, in developing ZL-6201, it wants to succeed where AbbVie disappointed.
Avenzo follows Bristol’s lead
The private group taps DualityBio for an EGFR x HER3 ADC.
